Palm Beach, FL – April 8, 2020 – A new “diabetic” nutritional fiber recognized by the Food & Drug Administration (FDA) and shown in clinical data to slow the body’s absorption of sugar and improve overall blood sugar levels is just now finding its way into products catering to America’s millions of diabetics – and in the process is creating a sizeable market opportunity for top companies like Archer Daniels Midland Co. (NYSE:ADM), Glucose Health, Inc. (OTC: GLUC) Procter & Gamble Co. (NYSE: PG), GlaxoSmithKline PLC (NYSE: GSK) and even Tilray Inc. (NASDAQ: TLRY).
According to the latest 2020 statistics compiled by the U.S. Centers for Disease Control & Prevention (CDC), 34.2 million Americans are diagnosed diabetics, with 90% having preventable, adult onset diabetes, also known as Type-2. Four years ago, Archer Daniels Midland Co. submitted dozens of clinical studies to the FDA concerning an entirely new form of nutritional dietary fiber it was developing, certain to find a market with America’s growing diabetic population. FDA issued new regulations with the effect that ADM’s dietary fiber can be referred to as such, finally paving the way for introduction of new food and beverage products containing its special fiber. According to MarketBeat.com, Stifel Nicolaus issued an updated buy rating on ADM on April 1, 2020, with a $49 price target.
Among the first products to reach retailer shelves utilizing ADM’s innovative new fiber is GlucoDown, made by Glucose Health, Inc. (OTC: GLUC). Using a special manufacturing process, the company “agglomerates” ADM’s fiber together with tea powder. The result is America’s first “healthy” diabetic iced tea. GlucoDown quickly gained the attention of buyers at Walmart and the product is now stocked at Walmart’s superstores nationwide. Not surprisingly, with iced tea the most popular of all non-carbonated soft drinks and millions of diabetics to sell to, Glucose Health, Inc. (OTC: GLUC) reported record revenues in its annual report filing last month.
For decades, Procter and Gamble’s (NYSE: PG) Metamucil brand has helped consumers with what P&G politely terms, “regularity”. But it turns out the very type of nutritional fiber used in Metamucil – psyllium – has also shown similar positive effects on blood sugar metabolism as ADM’s fiber, in clinical research. The FDA has approved a qualified health claim for psyllium, allowing the statement that the fiber reduces the risk of Type-2 diabetes, but with the caveat that the clinical data reported, is from relatively few studies. On March 30, Jefferies upgraded PG to a buy, according to MarketBeat.com.3
A third form of diabetic fiber, found in Benefiber, manufactured by the consumer product arm of pharmaceutical giant GlaxoSmithKline (NYSE: GSK), also has clinical data indicating promising benefits related to blood sugar metabolism although no health claims have yet been submitted to FDA. And now, even CBD companies have gained a foothold in the market to serve diabetic consumers. Tilray (NASDAQ: TLRY), one of the world’s largest medical cannabis suppliers, acquired start-up hemp fiber company Manitoba Harvest last year, in a deal worth $317 million. CBD devotees passionately advocate that hemp fiber has benefit for persons with diabetes. However, to date, clinical studies and FDA applications have yet to been undertaken.
Other related developments from around the markets include:
Archer Daniels Midland Co. (ADM) announced an ambitious new plan to reduce its greenhouse gas emissions by 25 percent and its energy intensity by 15 percent by 2035. “Every single day, ADM is focused on keeping its employees healthy and safe while simultaneously ensuring we are continuing to support the world’s food supply,” said Chairman and CEO Juan Luciano.
Glucose Health Inc. (GLUC) announced a 224% sales increase year-over-year from its Amazon store. Amazon awarded GlucoDown® an “Amazon Choice” designation and GlucoDown® routinely leads Amazon’s consumer search results for the diabetic drinks category.
Procter & Gamble Co. (PG) will webcast a discussion of its third quarter earnings results on Tuesday, April 21, 2020 beginning at 8:30 a.m. ET. Media and investors may access the live audio webcast at www.pginvestor.com beginning at 8:30 a.m. ET. The webcast will also be available for replay.
GlaxoSmithKline PLC (GSK) and Vir Biotechnology, Inc. announced they have signed a binding agreement to enter into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration will use Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventative options to help address the current COVID-19 pandemic and future outbreaks.
Tilray Inc. (TLRY) reported financial results for the fourth quarter and full fiscal year ended December 31, 2019. “Our full year results demonstrate strong sales growth momentum, which we expect to continue in 2020,” said Brendan Kennedy, Tilray’s Chief Executive Officer. “
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated nineteen hundred dollars for news coverage of the current press release issued by Glucose Health, Inc., by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact email: firstname.lastname@example.org – +1(561)325-8757